Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · IEX Real-Time Price · USD
26.00
+0.17 (0.66%)
At close: May 2, 2024, 4:00 PM
25.50
-0.50 (-1.92%)
After-hours: May 2, 2024, 4:51 PM EDT
Dyne Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
123
Market Cap
2.11B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CONMED | 1.26B |
Amphastar Pharmaceuticals | 644.40M |
TG Therapeutics | 233.66M |
Deciphera Pharmaceuticals | 163.36M |
Kymera Therapeutics | 78.59M |
Intellia Therapeutics | 36.28M |
NewAmsterdam Pharma Company | 15.66M |
Keros Therapeutics | 151.00K |
DYN News
- 2 hours ago - Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics Announces CEO Transition - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference - GlobeNewsWire
- 3 months ago - Dyne Therapeutics to Present at February Investor Conferences - GlobeNewsWire